New research criteria for Alzheimer’s disease (AD) and mild cognitive impairment (MCI) emphasize the use of imaging biomarkers in clinical diagnosis of these disorders. The volume loss of medial temporal lobe structures, especially hippocampal atrophy, is the best validated marker of AD. Manual tracing on MRI is the present gold standard for evaluating hippocampal volume; however, it is laborious and tracer-dependent. We categorized the most recent full- or semi-automated methods by the nature of the output of the method: size and shape of subcortical structures, cortical thickness, atrophy-rate and voxel- and region-based characteristics. The features of each method are introduced. The findings in structural MRI studies, especially in those studies utilizing the most recent methods, and the accuracies of those new methods in differentiating AD from healthy controls and stable MCI from progressive MCI are reviewed.
|Journal||Neurodegenerative Disease Management|
|Publication status||Published - 2012|
|MoE publication type||A1 Journal article-refereed|
- Alzheimers disease
- image quantification